Medication info
Micosil Tablet (Terbinafine Hydrochloride)

Micosil Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Dae Won Pharmaceutical Co., Ltd.
Appearance
White to whitish round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200001859 · Notified 2000.01.28 · Insurance code 671801740

Summary

Main use
Treatment of onychomycosis, cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis in children
Who takes it
Adults · Children
Adult dose
Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. Infections of the fingernails or relatively small toenails, or in younger patients, may require a shorter treatment period of 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL per minute, reduce the daily dose by 1/2.
Child dose
Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
Dae Won Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis in children

  • Dermatophyte infections
  • athlete's foot
  • tinea corporis
  • tinea capitis
  • onychomycosis
View approved original text

This medication is used for the treatment of dermatophyte infections caused by dermatophytes, such as athlete's foot, tinea corporis, tinea capitis, and onychomycosis in adults. It is also used for treating tinea capitis in children.

How to take

Adult dose

Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. Infections of the fingernails or relatively small toenails, or in younger patients, may require a shorter treatment period of 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL per minute, reduce the daily dose by 1/2.

Child dose

Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This medication is not recommended for patients with chronic or active hepatic disease with impaired liver function. Due to the risk of liver damage, liver function tests should be conducted before starting this medication and regularly monitored during treatment. If any symptoms of liver dysfunction occur, the use of this medication should be discontinued immediately and the physician should be informed. This medication should not be used in patients with blood disorders, severe renal impairment, nursing mothers, or children under 2 years of age. Patients with certain genetic disorders such as lactose intolerance should also avoid this medication. Elderly patients over 65 years or children weighing less than 20 kg, and patients with impaired kidney function should use this medication cautiously. This medication may rarely cause serious skin reactions, so if any abnormal skin symptoms occur, it should be stopped immediately. This medication can cause dizziness or drowsiness, so caution should be taken when driving or operating machinery. There may be interactions when used with other drugs, so any medications being taken should be disclosed to a doctor or pharmacist. Women who are pregnant or may become pregnant should use this medication with caution, and nursing mothers should discontinue breastfeeding while on this medication. In case of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may occur; immediate medical attention should be sought if these symptoms appear. This medication should be kept out of reach of children and stored at room temperature away from direct sunlight.

Side effects

Liver failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphedema, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, discomfort in the stomach, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, paresthesia, sensory decrease, decreased attention, insomnia, elevated BUN, polyuria, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglycerides, fatigue, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, elevated blood creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent moisture and air from entering, preferably at a temperature between 1°C to 30°C. Storing it this way helps maintain the medication's effectiveness for an extended period.

Appearance and packaging

Appearance

White to whitish round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.